

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-47 (Canceled)

Claim 48 (Previously presented) A method of enhancing wound healing in a patient, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

Claim 49 (Previously presented) The method of claim 48, wherein the wound healing is selected from the group consisting of burns, surgical incisions, lacerations, ulcers, and traumas.

Claim 50 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 51 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 52 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 53 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 54 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 55 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 56 (Currently amended) The ~~mutein~~ method of claim 48, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

Claim 57 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr101~~] [Tyr¹⁰¹].

Claim 58 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr137~~] [Tyr¹³⁷].

Claim 59 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr89, 101~~] [Tyr^{89, 101}].

Claim 60 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr89, 137~~] [Tyr^{89, 137}].

Claim 61 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr101, 137~~] [Tyr^{101, 137}].

Claim 62 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr89, 101-137~~] [Tyr^{89, 101, 137}].

Claim 63 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein is administered topically.

Claim 64 (Currently amended) The ~~mutein~~ method of claim 48, wherein the mutein is administered parenterally.

Claim 65 (Previously presented) A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has heart disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

Claim 66 (Previously presented) The method of claim 65, wherein the patient has coronary artery disease.

Claim 67 (Previously presented) The method of claim 65, wherein the patient has myocardial infarction.

Claim 68 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 69 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 70 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 71 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 72 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 73 (Currently amended) The mutein of claim 65, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 74 (Currently amended) The ~~mutain~~ method of claim 65, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

Claim 75 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] is human basic fibroblast growth factor ~~{Tyr101}~~ [Tyr¹⁰¹].

Claim 76 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] is human basic fibroblast growth factor ~~{Tyr137}~~ [Tyr¹³⁷].

Claim 77 (Currently amended) The ~~mutain~~ method of claim 65, which is human basic fibroblast growth factor ~~{Tyr⁸⁹, 101}~~ [Tyr⁸⁹, 101].

Claim 78 (Currently amended) The ~~mutain~~ method of claim 65, which is human basic fibroblast growth factor ~~{Tyr⁸⁹, 137}~~ [Tyr⁸⁹, 137].

Claim 79 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] is human basic fibroblast growth factor ~~{Tyr101, 137}~~ [Tyr¹⁰¹, 137].

Claim 80 (Currently amended) The ~~mutain~~ method of claim 65, wherein the mutein [[which]] is human basic fibroblast growth factor ~~{Tyr⁸⁹, 101-137}~~ [Tyr⁸⁹, 101, 137].

Claim 81 (Currently amended) The ~~mutein~~ method of claim 65, wherein the mutein is administered topically.

Claim 82 (Currently amended) The ~~mutein~~ method of claim 65, wherein the mutein is administered parenterally.

Claim 83 (Previously presented) A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has peripheral vascular disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

Claim 84 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for [[Glu89]] [Glu⁸⁹].

Claim 85 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 86 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 87 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for [[Glu89]] [Glu⁸⁹].

Claim 88 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 89 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 90 (Currently amended) The ~~mutein~~ method of claim 83, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

Claim 91 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr101]~~ [Tyr¹⁰¹].

Claim 92 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr~~¹³⁷] [~~Tyr~~¹³⁷].

Claim 93 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr~~^{89, 101}] [~~Tyr~~^{89, 101}].

Claim 94 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr~~^{89, 137}] [~~Tyr~~^{89, 137}].

Claim 95 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr~~^{101, 137}] [~~Tyr~~^{101, 137}].

Claim 96 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr~~^{89, 101-137}] [~~Tyr~~^{89, 101, 137}].

Claim 97 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein is administered topically.

Claim 98 (Currently amended) The ~~mutein~~ method of claim 83, wherein the mutein is administered parenterally.

Claim 99 (Previously presented) A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has neural injury, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

Claim 100 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for [[Glu⁸⁹]] [~~Glu~~⁸⁹].

Claim 101 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Asp~~¹⁰¹ [~~Asp~~¹⁰¹].

Claim 102 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a hydrophobic amino acid for ~~Leu~~¹³⁷ [~~Leu~~¹³⁷].

Claim 103 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for [[Glu89]] [Glu⁸⁹].

Claim 104 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 105 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 106 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

Claim 107 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr101]~~ [Tyr¹⁰¹].

Claim 108 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr137]~~ [Tyr¹³⁷].

Claim 109 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr89, 101]~~ [Tyr^{89, 101}].

Claim 110 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr89, 137]~~ [Tyr^{89, 137}].

Claim 111 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr101, 137]~~ [Tyr^{101, 137}].

Claim 112 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr89, 101, 137]~~ [Tyr^{89, 101, 137}].

Claim 113 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein is administered topically.

Claim 114 (Currently amended) The ~~mutein~~ method of claim 99, wherein the mutein is administered parenterally.

Claim 115 (Previously presented) A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has ischemia, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide

thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

Claim 116 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 117 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 118 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 119 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu⁸⁹].

Claim 120 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp¹⁰¹].

Claim 121 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu¹³⁷].

Claim 122 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

Claim 123 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr101]~~ [Tyr¹⁰¹].

Claim 124 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr137]~~ [Tyr¹³⁷].

Claim 125 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr89, 101]~~ [Tyr^{89, 101}].

Claim 126 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr89, 137]~~ [Tyr^{89, 137}].

Claim 127 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr^{101, 137}~~] [Tyr^{101, 137}].

Claim 128 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr^{89, 101-137}~~] [Tyr^{89, 101, 137}].

Claim 129 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein is administered topically.

Claim 130 (Currently amended) The ~~mutein~~ method of claim 115, wherein the mutein is administered parenterally.